Skip to content
10-Q

Quarterly Report

PROVECTUS BIOPHARMACEUTICALS, INC. PVCT

0001641172-25-010273

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 12, 2025 420.28M sh
Stockholders Equity Q1 2025 · Mar 31, 2025 −$5.1M
Stockholders Equity Q1 2025 · Dec 31, 2024 −$5.96M
Current Liabilities Q1 2025 · Mar 31, 2025 $5.74M
Current Liabilities Q1 2025 · Dec 31, 2024 $6.98M
Total Liabilities Q1 2025 · Mar 31, 2025 $5.74M
Total Liabilities Q1 2025 · Dec 31, 2024 $6.98M
Current Assets Q1 2025 · Mar 31, 2025 $649.47K
Current Assets Q1 2025 · Dec 31, 2024 $976.77K
Total Assets Q1 2025 · Mar 31, 2025 $666.26K
Total Assets Q1 2025 · Dec 31, 2024 $1.01M
Shares Diluted Q1 2025 · Mar 31, 2024 419.52M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$1.04M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $18.04K
Eps Diluted Q1 2025 · Mar 31, 2024 $0.00
Sga Expense Q1 2025 · Mar 31, 2024 $129.8K
Rd Expense Q1 2025 · Mar 31, 2024 $555.54K
Net Income Q1 2025 · Mar 31, 2024 −$504.04K
Operating Income Q1 2025 · Mar 31, 2024 −$447.27K
Revenue Q1 2025 · Mar 31, 2024 $238.07K